Refine
Has Fulltext
- yes (73)
Is part of the Bibliography
- yes (73)
Year of publication
Document Type
- Journal article (67)
- Doctoral Thesis (6)
Keywords
- ischemic stroke (6)
- mechanical thrombectomy (4)
- chemotherapy (3)
- cochlear implantation (3)
- neutrophils (3)
- thrombo-inflammation (3)
- 3D fluoroscopy (2)
- Childhood medulloblastoma (2)
- Clinical Neuroradiology (2)
- Kernspintomografie (2)
- Pädiatrie (2)
- Radiotherapy (2)
- acute ischemic stroke (2)
- aortic arch (2)
- atherosclerosis (2)
- cerebellar tDCS (2)
- children (2)
- cognitive impairment (2)
- editorial (2)
- fpVCT (2)
- immunohistochemistry (2)
- intracranial bleeding (2)
- intraoperative imaging (2)
- ischemic penumbra (2)
- magnetic resonance imaging (2)
- middle cerebral artery occlusion (2)
- mouse (2)
- multiple sclerosis (2)
- neurology (2)
- radiotherapy (2)
- split-belt treadmill (2)
- stroke (2)
- surgery (2)
- temporal bone (2)
- three-dimensional imaging (2)
- 3 D rotational fluoroscopy (1)
- 3D analysis (1)
- 4D flow (1)
- 4D flow MRI (1)
- APERIO (1)
- APERIO Hybrid (1)
- AQP4 (1)
- AT/RT (1)
- Activation (1)
- Adolescents (1)
- Alemtuzumab (1)
- Alzheimer’s dementia (1)
- Anwenderfreundlichkeit (1)
- Atherosclerosis, intracranial arteries (1)
- B cells (1)
- B7-H1 Antigen (1)
- Blutstillung (1)
- Brain atrophy (1)
- CD19 (1)
- CD52 (1)
- CDL (1)
- CMR (1)
- CNS (1)
- CNS imaging (1)
- COVID-19 (1)
- CT (1)
- CTLA-4 Antigen (1)
- CXCL4 (1)
- CXCL7 (1)
- Chemotherapy (1)
- Childrens-cancer (1)
- Chronic heart failure (1)
- Cisplatin (1)
- Clinical Genetics (1)
- Clinical trial (1)
- Cochlear duct length (1)
- Cochlear planning software (1)
- Cochlear-Implantat (1)
- Cognitive decline (1)
- Computertomografie (1)
- Covid-19 (1)
- DWI (1)
- Down-regulation (1)
- Druckverband (1)
- Druckverbände (1)
- Drug Therapy, Combination (1)
- EAE (1)
- EU‐RHAB Registry (1)
- Enhancement (1)
- Ependymom (1)
- Ependymoma (1)
- Extraocular eye muscles (1)
- Fabry disease (1)
- Fibroblasts (1)
- GFAP (1)
- Gene (1)
- Glial fibrillary acidic protein (1)
- Gliom (1)
- Großgefäßverschluss (1)
- HD (1)
- HMGB1 (1)
- High-dose chemotherapy (1)
- Hirnkrankheit / Ischämie (1)
- Hirntumor (1)
- Induced apoptosis (1)
- Intrakranielle Blutung (1)
- Kinder (1)
- Kinderheilkunde (1)
- Kontrastmittel (1)
- Lines (1)
- MPI (1)
- MPS (1)
- MR neurography (1)
- MRI (1)
- MS (1)
- MSCT (1)
- MTX (1)
- Medulloblastoma (1)
- Melanoma-cells (1)
- Memory dysfunction (1)
- Meniere’s disease (1)
- Metastases (1)
- Mucopolysaccharidosis IIIa (1)
- NAP-2 (1)
- NETs (1)
- NMOSD (1)
- NOAC (1)
- Neuroradiologie (1)
- Neuroradiology (1)
- Orai2 (1)
- PET/CT (1)
- PF4 (1)
- PWV (1)
- Paediatric (1)
- Paediatrics (1)
- Parkinson’s disease (1)
- Patientenfreundlichkeit (1)
- Phase II trials (1)
- Phase-II (1)
- Preoperative radiological diagnostics (1)
- Primitive neuroectodermal (1)
- Programmed Cell Death 1 Receptor (1)
- Prophylaxe (1)
- Präoperative radiologische Diagnostik (1)
- Pseudoprogress (1)
- R-CHOP (1)
- Recurrent medulloblastoma (1)
- Reirradiation (1)
- Relapse (1)
- Rhabdoid 2007 (1)
- Rhabdomyosarcoma (1)
- Schlaganfall (1)
- Schütteltrauma (1)
- Secondary tumours (1)
- Skin Neoplasms (1)
- Strahlentherapie (1)
- Studie (1)
- Suprascapular nerve (1)
- Survival (1)
- T-cells (1)
- Therapy (1)
- Treatment (1)
- Trial (1)
- Tumors (1)
- Vergleich (1)
- Vitamin-K-Mangel-Blutung (1)
- WSS (1)
- adverse events (1)
- age (1)
- anatomy (1)
- aneurysm (1)
- aneurysm surgery (1)
- angiography (1)
- arterielle Blutgasanalyse (1)
- balance (1)
- biochemical assays (1)
- biomarker (1)
- biomedical engineering (1)
- blood–brain barrier (1)
- bone imaging (1)
- brain cancer (1)
- brain endothelium (1)
- carotid atherosclerosis (1)
- carotid stenosis (1)
- carotid ultrasound (1)
- case report (1)
- cerebral ischemia (1)
- cerebral vasospasm (1)
- cerebrovascular disorders (1)
- cervical dystonia (1)
- characterization and analytical techniques (1)
- chemokines (1)
- childhood cancer (1)
- cholinergic activity (1)
- chronic heart failure (1)
- classification (1)
- clinical trials (1)
- clip control (1)
- cluster analysis (1)
- collateral circulation (1)
- comparison (1)
- compression syndrome (1)
- computed tomography (1)
- consolidation (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- cortical excitability (1)
- cortical silent period (1)
- crosslinked coating (1)
- degree of stenosis (1)
- diabetic polyneuropathy (1)
- diagnosis (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diffuse large B-cell lymphoma (1)
- disease risk-factors (1)
- dorsal root ganglion (1)
- editorial board (1)
- edoxaban (1)
- electrical and electronic engineering (1)
- electromagnetic navigation (1)
- electromyographic (1)
- encephalopathy (1)
- endoglin (1)
- endotheliitis (1)
- ependymoma (1)
- experimental stroke (1)
- facial nerve (1)
- fibromyalgia syndrome (1)
- fiducial registration error (1)
- flexible CO2 laser (1)
- flow (1)
- flow dynamics (1)
- fluoroscopy (1)
- frameless systems (1)
- functional MRI (1)
- gait (1)
- gene variant (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- german multicenter (1)
- giant cell arteritis (1)
- glial fibrillary acidic protein (1)
- glycoprotein VI (1)
- glycoprotein receptor Ib (1)
- glycoprotein receptor Ibα (1)
- guality-of-life (1)
- heart failure (1)
- hemorrhagic transformation (1)
- hepatitis B virus (1)
- human behaviour (1)
- hyperperfusion (1)
- hypoxia (1)
- image quality (1)
- imaging (1)
- imaging agents (1)
- imaging changes (1)
- inebilizumab (1)
- integrin α2 (1)
- intensity of attention (1)
- interelectrode-distance (1)
- intraoperative (1)
- intraventricular therapy (1)
- ischämischer Schlaganfall (1)
- journal (1)
- jugular paraganglioma (1)
- large artery vasculitis (1)
- large vessel occlusion (1)
- laser surgery (1)
- lateral skull base (1)
- length of stenosis (1)
- leukocytes (1)
- levodopa-induced dyskinesia (1)
- locomotor adaptation (1)
- long-term survivors (1)
- longitudinally extensive transverse myelitis (1)
- low-grade glioma (1)
- lymphoma (1)
- lysosomal storage disease (1)
- magnetic properties (1)
- magnetic properties and materials (1)
- magnetic resonance neurography (1)
- mapping (1)
- mass index (1)
- mechanische Thrombektomie (1)
- medical imaging (1)
- medulloblastoma (1)
- mice (1)
- microscopy (1)
- molecular neuroscience (1)
- motor-evoked potentials (MEP) (1)
- nanoparticles (1)
- neck circumference (1)
- neurofilament light chain (1)
- neurological complications (1)
- neuropathic pain (1)
- neuropathy (1)
- neurosurgery (1)
- neurovascular disorders (1)
- niedriggradig maligne hirneigene Tumore (1)
- niedrigmaligne (1)
- onset craniopharyngioma (1)
- ophthalmic artery (1)
- optic nerve (1)
- optic neuritis (1)
- orbit (1)
- otology (1)
- outcome (1)
- p.R245H (1)
- p.S298P (1)
- patient comfort (1)
- pediatric brain tumor (1)
- pediatric low‐grade glioma (1)
- perfusion imaging (1)
- peripheral nerve involvement (1)
- peripheral nervous system (1)
- permeability imaging (1)
- personalized medicine (1)
- phosphorylated tau protein (1)
- plaque (1)
- plaque characteristics (1)
- platelets (1)
- post-processing (1)
- predictive markers (1)
- pressure bandages (1)
- prognosis (1)
- progression (1)
- prophylaxis (1)
- proton beam therapy (1)
- psychiatric disorders (1)
- pulse wave velocity (1)
- quantification (1)
- radial (1)
- radiatio (1)
- re-irradiation (1)
- recombinant tissue-type plasminogen activator (1)
- recurrence (1)
- recurrent (1)
- refractory (1)
- renal function (1)
- reperfusion injury (1)
- research activity (1)
- risk of fall (1)
- saccotomy (1)
- secondary reconstruction (1)
- secondary stroke injury (1)
- self-navigation (1)
- seronegative (1)
- shaken baby syndrome (1)
- shedding (1)
- shoulder neurolysis (1)
- sirolimus (1)
- software (1)
- stent-retriever device (1)
- stereotaxy (1)
- study (1)
- subarachnoid hemorrhage (1)
- subcutaneous adipose-tissue (1)
- suprascapular notch (1)
- surgical management of paraganglioma (1)
- tMCAO (1)
- thrombemboli (1)
- thromboemboli (1)
- to-height ratio (1)
- tomography (1)
- transcranial magnetic simulation (TMS) (1)
- transient middle cerebral artery occlusion (1)
- tympanic paraganglioma (1)
- tympanojugular paraganglioma (1)
- user convenience (1)
- vasa vasorum (1)
- vertebral artery (1)
- vessel diameter (1)
- vessel patency (1)
- vestibular aqueduct (VA) (1)
- visceral adiposity (1)
- vitamin k deficiency bleeding (1)
- wall shear stress (1)
- zerebrale Ischämie (1)
Institute
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (73) (remove)
Sonstige beteiligte Institutionen
Background
In acute ischemic stroke, cessation of blood flow causes immediate tissue necrosis within the center of the ischemic brain region accompanied by functional failure in the surrounding brain tissue designated the penumbra. The penumbra can be salvaged by timely thrombolysis/thrombectomy, the only available acute stroke treatment to date, but is progressively destroyed by the expansion of infarction. The underlying mechanisms of progressive infarction are not fully understood.
Methods
To address mechanisms, mice underwent filament occlusion of the middle cerebral artery (MCAO) for up to 4 h. Infarct development was compared between mice treated with antigen-binding fragments (Fab) against the platelet surface molecules GPIb (p0p/B Fab) or rat immunoglobulin G (IgG) Fab as control treatment. Moreover, Rag1\(^{−/−}\) mice lacking T-cells underwent the same procedures. Infarct volumes as well as the local inflammatory response were determined during vessel occlusion.
Results
We show that blocking of the platelet adhesion receptor, glycoprotein (GP) Ibα in mice, delays cerebral infarct progression already during occlusion and thus before recanalization/reperfusion. This therapeutic effect was accompanied by decreased T-cell infiltration, particularly at the infarct border zone, which during occlusion is supplied by collateral blood flow. Accordingly, mice lacking T-cells were likewise protected from infarct progression under occlusion.
Conclusions
Progressive brain infarction can be delayed by blocking detrimental lymphocyte/platelet responses already during occlusion paving the way for ultra-early treatment strategies in hyper-acute stroke before recanalization.
Platelet collagen interactions at sites of vascular injuries predominantly involve glycoprotein VI (GPVI) and the integrin α2β1. Both proteins are primarily expressed on platelets and megakaryocytes whereas GPVI expression is also shown on endothelial and integrin α2β1 expression on epithelial cells. We recently showed that depletion of GPVI improves stroke outcome without increasing the risk of cerebral hemorrhage. Genetic variants associated with higher platelet surface integrin α2 (ITGA2) receptor levels have frequently been found to correlate with an increased risk of ischemic stroke in patients. However until now, no preclinical stroke study has addressed whether platelet integrin α2β1 contributes to the pathophysiology of ischemia/reperfusion (I/R) injury. Focal cerebral ischemia was induced in C57BL/6 and Itga2\(^{−/−}\) mice by a 60 min transient middle cerebral artery occlusion (tMCAO). Additionally, wild-type animals were pretreated with anti-GPVI antibody (JAQ1) or Fab fragments of a function blocking antibody against integrin α2β1 (LEN/B). In anti-GPVI treated animals, intravenous (IV) recombinant tissue plasminogen activator (rt-PA) treatment was applied immediately prior to reperfusion. Stroke outcome, including infarct size and neurological scoring was determined on day 1 after tMCAO. We demonstrate that targeting the integrin α2β1 (pharmacologic; genetic) did neither reduce stroke size nor improve functional outcome on day 1 after tMCAO. In contrast, depletion of platelet GPVI prior to stroke was safe and effective, even when combined with rt-PA treatment. Our results underscore that GPVI, but not ITGA2, is a promising and safe target in the setting of ischemic stroke.
Background:
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) for which several new treatment options were recently introduced. Among them is the monoclonal anti-CD52 antibody alemtuzumab that depletes mainly B cells and T cells in the immune periphery. Considering the ongoing controversy about the involvement of B cells and in particular the formation of B cell aggregates in the brains of progressive MS patients, an in-depth understanding of the effects of anti-CD52 antibody treatment on the B cell compartment in the CNS itself is desirable.
Methods:
We used myelin basic protein (MBP)-proteolipid protein (PLP)-induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 (B6) mice as B cell-dependent model of MS. Mice were treated intraperitoneally either at the peak of EAE or at 60 days after onset with 200 μg murine anti-CD52 vs. IgG2a isotype control antibody for five consecutive days. Disease was subsequently monitored for 10 days. The antigen-specific B cell/antibody response was measured by ELISPOT and ELISA. Effects on CNS infiltration and B cell aggregation were determined by immunohistochemistry. Neurodegeneration was evaluated by Luxol Fast Blue, SMI-32, and Olig2/APC staining as well as by electron microscopy and phosphorylated heavy neurofilament serum ELISA.
Results:
Treatment with anti-CD52 antibody attenuated EAE only when administered at the peak of disease. While there was no effect on the production of MP4-specific IgG, the treatment almost completely depleted CNS infiltrates and B cell aggregates even when given as late as 60 days after onset. On the ultrastructural level, we observed significantly less axonal damage in the spinal cord and cerebellum in chronic EAE after anti-CD52 treatment.
Conclusion:
Anti-CD52 treatment abrogated B cell infiltration and disrupted existing B cell aggregates in the CNS.
It’s time to go …
(2022)
Automated analysis of the inner ear anatomy in radiological data instead of time-consuming manual assessment is a worthwhile goal that could facilitate preoperative planning and clinical research. We propose a framework encompassing joint semantic segmentation of the inner ear and anatomical landmark detection of helicotrema, oval and round window. A fully automated pipeline with a single, dual-headed volumetric 3D U-Net was implemented, trained and evaluated using manually labeled in-house datasets from cadaveric specimen (N = 43) and clinical practice (N = 9). The model robustness was further evaluated on three independent open-source datasets (N = 23 + 7 + 17 scans) consisting of cadaveric specimen scans. For the in-house datasets, Dice scores of 0.97 and 0.94, intersection-over-union scores of 0.94 and 0.89 and average Hausdorf distances of 0.065 and 0.14 voxel units were achieved. The landmark localization task was performed automatically with an average localization error of 3.3 and 5.2 voxel units. A robust, albeit reduced performance could be
attained for the catalogue of three open-source datasets. Results of the ablation studies with 43 mono-parametric variations of the basal architecture and training protocol provided task-optimal parameters for both categories. Ablation studies against single-task variants of the basal architecture showed a clear performance beneft of coupling landmark localization with segmentation and a dataset-dependent performance impact on segmentation ability.
Purpose
Patients suffering from aggressive systemic peripheral lymphoma with primary central nervous system involvement (PCL) are a rare and sparsely investigated population. Recommended treatment regimens include a combination of intrathecal and systemic chemotherapy as well as whole brain radiotherapy while offering relatively poor survival.
Methods
We conducted a single-center retrospective study that analyzed safety and outcome of 4 + 4 cycles Rituximab (R)-CHOP and R-high-dose Methotrexate (HD-MTX) for newly diagnosed, transplant-eligible patients ("Ping-Pong"), followed by Cytarabine (AraC)/Thiotepa (TT), BCNU/TT, and autologous hematologic stem cell transplantation (aHSCT). We retrospectively analyzed a set of 16 patients with high-intermediate or high-risk IPI status.
Results
Overall response rate to Ping-Pong was 100% measured by CT/MRI, including 93.75% complete remissions after BCNU/TT followed by PBSCT. One patient failed to qualify for high-dose chemotherapy due to progression when receiving Cytarabine/TT. All patients experienced grade III adverse events, 3 of them a grade IV adverse event. Estimated progression-free survival is 93.75% after a 4.8-year follow-up currently.
Conclusion
Our study suggests high effectivity of R-CHOP with mid-cycle MTX with aHSCT consolidation towards acceptable OS results in this challenging patient population.
Context:
Hypothalamic obesity, cardiovascular disease (CVD), and relapse/progression have a major impact on prognosis in childhood-onset craniopharyngioma (CP). We analyzed nuchal skinfold thickness (NST) on magnetic resonance imaging performed for follow-up monitoring as a novel parameter for body composition (BC) and CVD in CP.
Objective:
The objective of the study was to identify the association of NST with body mass index (BMI), waist to height ratio (WHtR), functional capacity, and blood pressure (BP) in CP and controls.
Design:
This was a cross-sectional and longitudinal prospective study in CP patients. Setting: The study was conducted at HIT-Endo, KRANIOPHARYNGEOM 2000/2007.
Patients:
Participants included 94 CP patients and 75 controls.
Interventions:
There were no interventions.
Main Outcome Measures:
Association of NST with BC and BP in 43 CP and 43 controls was measured.
Results:
NST correlated with BMI SD score (SDS; r = 0.78; P = .001; n = 169) and WHtR (r = 0.85; P = .001; n = 86) in the total cohort and CP patients (NST-BMI SDS: r = 0.77, P = .001, n = 94); NST-WHtR: r = 0.835, P = .001, n = 43) and controls (NST-BMI SDS: r = 0.792, P = .001, n = 75; NST-WHtR: r = 0.671, P = .001, n = 43). In CP, systolic BP correlated with NST (r = 0.575, P = .001), BMI SDS (r = 0.434, P = .004), and WHtR (r = 0.386, P = .011). Similar results were observed for diastolic BP in CP. In multivariate analyses, NST had a predictive value for hypertension in postpubertal CP and controls (odds ratio 6.98, 95% confidence interval 1.65, 29.5], P = .008). During a longitudinal follow-up, changes in NST correlated with changes in BMI SDS (P = .001) and WHtR (P = .01) but not with changes in BP and functional capacity.
Conclusions:
Because monitoring of magnetic resonance imaging and BC is essential for follow-up in CP, NST could serve as a novel and clinically relevant parameter for longitudinal assessment of BC and CVD risk in CP.